Loading...
Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302
INTRODUCTION: Radiographic imaging is used to monitor disease progression for men with metastatic castrate-resistant prostate cancer (mCRPC). The optimal frequency of imaging, a costly and limited resource, is not known. Our objective was to identify predictors of radiographic progression to inform...
Na minha lista:
| Udgivet i: | Can Urol Assoc J |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Canadian Medical Association
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6570594/ https://ncbi.nlm.nih.gov/pubmed/30407155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.5586 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|